Optimize Meds for Peripheral Artery Disease
August 2019
You'll hear debate about how to manage stable peripheral artery disease (PAD)...now that rivaroxaban (Xarelto) is approved for this use.
Think of managing PAD as similar to coronary artery disease...both are due to plaque buildup.
We know PAD patients have a high risk of complications...such as CV events or limb amputation. Plus they may develop symptoms...claudication or pain that reduces walking distance and quality of life.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote